TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03010527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab injections every four weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab injections every four weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab injections every four weeks (Q4W)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo injections every four weeks (Q4W)
Study: NCT01003847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate, fatty acid, placebo
Description: fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate, fatty acid, placebo
Description: fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate, fatty acid, placebo
Description: fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
Study: NCT01599663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management algorithm
Description: The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
Study: NCT00481819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506MR
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: oral
Study: NCT01841905

Intervention type: OTHER
Intervention: Observational Study
Description: Observational Study
Study: NCT02802839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Study: NCT01529073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
Study: NCT04208308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chia seeds supplementation (25 g)
Description: Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chia seeds supplementation (25 g)
Description: Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chia seeds supplementation (15 g)
Description: Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chia seeds supplementation (15 g)
Description: Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
Study: NCT02648490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
Study: NCT04208308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20
Description: Chia seeds - 1 daily dose Fish oil TID~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20
Description: Chia seeds - 1 daily dose Fish oil TID~Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)~On dose (15g) of chia seeds contains:~energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg
Study: NCT02648490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 inhibitor
Description: If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
Study: NCT04208308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Description: TID~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Description: TID~Daily dose:~Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)
Study: NCT01694381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5
Description: single point mutant of serine protease prourokinase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5
Description: single point mutant of serine protease prourokinase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1-inhibitor
Description: a protease inhibitor belonging to the serpin superfamily.
Study: NCT01934959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifico
Study: NCT04375917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic
Description: O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
Study: NCT03157375

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular Lens Implantation

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular Lens Implantation

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular Lens Implantation

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraocular Lens Implantation
Study: NCT03407937

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypnosis
Description: Hypnosis is a therapeutic method in which the experimenter or therapist make suggestions to individuals after they have undergone a hypnotic induction. This induction is a relaxation procedure designed to focus one's mind and to induce a hypnotic trance in individuals. The hypnotic trance consists in a state of deep absorption, concentration and altered sensations, cognitions and behaviors. Hypnosis can be used for pain control in experimental and clinical settings. In this study, standardized hypnosis including a relaxation technique for the hypnotic induction and a direct hypnotic analgesia technique for the hypnotic suggestions will be used.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meditation
Description: Meditation is a relaxation method that can be used to reduce pain symptoms and pain perception in clinical and experimental situations. In this study, a standardized mindfulness meditation session of 20 minutes will be used to induce a relaxation and an analgesic effect in participants. Mindfulness meditation is a practice intended to increase mindfulness and awareness of the self and the environment by techniques of controlled breathing, focus on neutral elements, and observation of one's thoughts and emotions without judgment.
Study: NCT03152695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound
Description: Local tumor ablation by ArcBlate (EpiSonica, Taiwan) will be performed, and the entire procedure will be monitored by MRI
Study: NCT02870998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active learning
Description: 1-day continuing education activity consisting of a lecture on patient education.
Study: NCT03407937

Intervention type: OTHER
Group type: OTHER
Intervention: Conditioned pain modulation
Description: Conditioned pain modulation (CPM) is a pain inhibition mechanism that is used to assess endogenous analgesia capacity. The method to evaluate CPM in healthy individuals and patients with pain includes both a conditioning stimulus (a noxious stimulus that induces CPM) and a test stimulus (a noxious stimulus used to evaluate the analgesic response to the conditioning stimulus). In this study, the conditioning stimulus will be a cold pressor test (two-minutes immersion of one hand in ice water) and the test stimulus will be a two-minutes thermal noxious stimulus delivered by a contact thermode.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: A placebo is a substance (or treatment) with no active therapeutic effect. The placebo effect (analgesia) in this study will be induced by the oral administration of one inert tablet (sugar pill). The tablet is a round, hard, white, flat-faced tablet with no active ingredient. The participant is told that the tablet is an active drug, more specifically an analgesic or a painkiller, that is used to achieve analgesia, relief from pain. This placebo condition is used to induce a diffuse analgesic effect in participants.
Study: NCT02870998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive learning
Description: 1-day continuing education activity consisting of a brief lecture on patient education and workshops.
Study: NCT01779232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: 100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
Study: NCT03552432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
Study: NCT01779232

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered daily like the active comparator
Study: NCT00482690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine polacrilex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine inhaler
Study: NCT04630392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: Ten minutes of treadmill walking at 110% self-selected overground walking speed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration & Treadmill Training
Description: Eight bouts of 90 seconds of vibration at 20 Hz and an amplitude of 2 mm on a Galileo Med-L side-to-side-alternating WBV plate (StimDesigns LLC, Carmel, CA, USA) followed by ten minutes of treadmill walking at 110% self selected overground walking speed.
Study: NCT03107338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEXKETOPROFEN TROMETAMOL
Description: Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
Study: NCT04399070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: The depression patients received propofol and S-ketamine before ECT
Study: NCT00954993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Period 1: Vaniprevir 600 mg twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg on Day 4. Period 2: Vaniprevir 300 mg twice daily on Days 1-3 and a single dose of Vaniprevir 300 mg on Day 4. There was at least a 30-day (up to approximately 140-day) washout interval between periods 1 and 2.
Study: NCT02620982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARIES (Extracorporal Shock Wave Application)
Description: The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
Study: NCT04041583

Intervention type: DEVICE
Intervention: Cervical Interfacet Spacers
Description: The use of Cervical Interfacet Spacers is a relatively novel technique shown to be useful for posterior fusion to address symptomatic pseudoarthrosis (fusion failure) after anterior cervical arthrodesis \[2\]. CIS have a relatively large osteoconductive surface area and are placed under tension in the interfacet space, which together favorably influence bony fusion \[2\].
Study: NCT03004729

Intervention type: OTHER
Group type: OTHER
Intervention: CoMiSS questionnaire
Study: NCT01982734

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: 80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: 80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: 80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: 80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals
Study: NCT03354117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate 30 MG Oral Tablet
Description: Each study participant will receive one dose of the study medication (ulipristal acetate 30mg plus meloxicam 15mg) at peak fertility in the treatment cycle.
Study: NCT01980329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Study: NCT01957878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProCervix
Description: ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
Study: NCT01724866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-2012
Description: SPI-2012 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-2012
Description: SPI-2012 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-2012
Description: SPI-2012 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim SC injection, per manufacturer's Prescribing Information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given based on standard dose for chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given based on standard dose for chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given based on standard dose for chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel given based on standard dose for chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide given based on standard dose for chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide given based on standard dose for chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide given based on standard dose for chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide given based on standard dose for chemotherapy.
Study: NCT01771978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Received 250 ml of a 5% dextrose solution as placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcystein
Description: Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
Study: NCT04399070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: The depression patients received propofol and ketamine before ECT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: The depression patients received propofol and saline before ECT
Study: NCT01771978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diltiazem and acetylcystein
Description: Received a combination of drug :diltiazem and acetylcystein~* bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution~* 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution
Study: NCT02420379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eteplirsen
Description: Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
Study: NCT04039126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION
Description: Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE
Description: 20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE
Description: 20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.
Study: NCT02209662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APIC-PRP
Description: APIC-PRP
Study: NCT00911248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC299
Description: PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression
Study: NCT01458639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technegas V SPECT imaging
Description: Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
Study: NCT02209662

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Saline plus standard of care
Description: Placebo, Saline plus standard of care
Study: NCT03919604

Intervention type: PROCEDURE
Intervention: Extracorporeal Life Support
Description: Any extracorporeal blood treatment technique for respiratory and/or cardiac support
Study: NCT00872989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Given orally
Study: NCT00606125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
Study: NCT02886273

Intervention type: OTHER
Intervention: Group 1
Description: Observation

Intervention type: OTHER
Intervention: Group 2
Description: Observation

Intervention type: OTHER
Intervention: Group 3
Description: Observation

Intervention type: OTHER
Intervention: Group 4
Description: Observation